Market Cap
₹34,883 Cr.
P/E
0.00
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Forensics

10 Yes

Positive for this company

2 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE
Latest
3.14%
3yr Average
9.08%
5yr Average
11.3%
Net Profit Margin
Latest
2.29%
3yr Average
6.27%
5yr Average
7.09%
ROCE
Latest
15.85%
3yr Average
17.22%
5yr Average
17.22%
Debt to Equity
Latest
0.46
3yr Average
0.51
5yr Average
0.62
Market Share
1.90% (as of Jul 22)
Anti - Diabetes - Market Share
15% (as of Mar 18)
Anti Dandruff Shampoo (Scalpe+) Market Share
2.38% (as of Jul 22)
Anti-Infectives - Market Share
0.35% (as of Nov 21)
Antineo Plastic - Market Share
4.12% (as of Jul 22)
Cardiovascular - Market Share
8.80% (as of Nov 21)
Dermatology - Market Share
0.01% (as of Feb 21)
Endocrinology - Market Share
0.09% (as of Jul 22)
Gastro-Intestinal - Market Share
0.01% (as of Nov 21)
Gynecology - Market Share
0.12% (as of Nov 21)
Neurological - Market Share
1.40% (as of Nov 21)
Ophthalmology - Market Share
0.10% (as of Nov 21)
Pain - Market Share
2.10% (as of Dec 22)
Pharmaceutical Sector - Market Share
5.48% (as of Nov 21)
Respiratory - Market Share
0.19% (as of Nov 21)
Stomatological - Market Share
0.02% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Product Wise Break-Up -Glenmark Pharma (Branded generics)

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Asset Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    Select a Metric
    • Number of ANDA's Filed in USA (.)
    • Number of ANDA's Approved By USFDA (.)
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis